Scott Minick
Executive Chairman at Aira
San Francisco Bay Area
Overview
Work Experience
Board Member
2024 - Current
BPGbio is a clinical-stage biopharma company that uses AI and patient biology to de-risk and accelerate drug discovery.
Raised $480,000,000.00.
Advisor
2021
Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.
Raised $257,204,774.00 from Alerce Medical Technology Partners.
Board Member
2012
Beth Israel Deaconess Medical Center is a health care system that brings together academic medical centers and teaching hospitals.
Raised $5,580,652.00 from Parkinson's Foundation, BIRD Foundation, MassAITC, Society to Improve Diagnosis in Medicine and Massachusetts Life Sciences Center.
Member Board of Trustees
2016 - 2022
Venture Partner
2008 - 2021
Managing Director
1998 - 2010
ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Executive Chairman
2016 - 2020
Aira provides tech-enabled services for the 300 million visually impaired people around the globe.
Raised $35,565,000.00 from Bose Ventures, Arboretum Ventures, Lux Capital, ARCH Venture Partners, Felicis and Jazz Venture Partners.
Member Board of Directors
2007 - 2019
Member Board of Directors
2012 - 2017
Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.
Raised $257,204,774.00 from Alerce Medical Technology Partners.
CEO
2010 - 2015
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.
Raised $91,847,684.00 from RUSNANO.
Director
2006 - 2014
Director
2006 - 2014